VTRS logo

Viatris Inc. (VTRS)

$20.45

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on VTRS

Market cap

$23.44B

EPS

-0.57

P/E ratio

--

Price to sales

1.37

Dividend yield

2.347%

Beta

0.896497

Price on VTRS

Previous close

$20.74

Today's open

$20.61

Day's range

$20.41 - $20.68

52 week range

$10.15 - $21.20

Profile about VTRS

CEO

Scott A. Smith

Employees

30000

Headquarters

Canonsburg, PA

Exchange

Nasdaq Global Select

Shares outstanding

1.15B

Issue type

Common Stock

VTRS industries and sectors

Healthcare

Pharmaceuticals

News on VTRS

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Viatris Inc. (VTRS) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 3 hours ago

news preview

Viatris Inc. (VTRS) Presents at UBS Global Biopharma Conference 2026 Transcript

Viatris Inc. (VTRS) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • Nov 17, 2026

news preview

Are Investors Undervaluing Viatris (VTRS) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

news source

Zacks Investment Research • a day ago

news preview

Viatris Completes Acquisition of Pacira BioSciences

PITTSBURGH, Nov. 17, 2026 /PRNewswire/ -- Viatris Inc. ("Viatris") (Nasdaq: VTRS), a global healthcare company, today announced that it has completed its acquisition of Pacira BioSciences, Inc. ("Pacira") (Nasdaq: PCRX), a leader in non-opioid pain management. The transaction was first announced on Oct. 8, 2026.

news source

PRNewsWire • Nov 17, 2026

news preview

CADILLAC FORMULA 1® TEAM WELCOMES VIATRIS AS OFFICIAL GLOBAL PHARMACEUTICAL PARTNER

Multiyear partnership brings together a U.S.-based global healthcare company and America's new Formula 1® team INDIANAPOLIS and PITTSBURGH, Nov. 16, 2026 /PRNewswire/ -- The Cadillac Formula 1® Team and Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced a multiyear partnership that makes Viatris the team's Official Global Pharmaceutical Partner, beginning in 2027. The partnership connects motorsport and medicine, two industries where precision, reliability and performance matter.

news source

PRNewsWire • Nov 16, 2026

news preview

Viatris Named to Fortune's World's Best Workplaces™ List for Second Consecutive Year

PITTSBURGH, Nov. 12, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Fortune's World's Best Workplaces™ list for the second consecutive year, recognizing the Company's commitment to fostering a workplace where colleagues feel valued, supported and empowered to make an impact. The list recognizes 25 global organizations based on Great Place To Work's (GPTW) rigorous assessment process, which includes confidential employee feedback.

news source

PRNewsWire • Nov 12, 2026

news preview

Viatris to Participate in Upcoming Investor Conferences

PITTSBURGH, Nov. 11, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in fireside chats at three upcoming healthcare conferences. The UBS Global Biopharma Conference on November 17, 2026, at 10 a.m.

news source

PRNewsWire • Nov 11, 2026

news preview

Viatris Inc. (VTRS) Hit a 52 Week High, Can the Run Continue?

Viatris (VTRS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

news source

Zacks Investment Research • Nov 10, 2026

news preview

VTRS or DHR: Which Is the Better Value Stock Right Now?

Investors interested in Medical Services stocks are likely familiar with Viatris (VTRS) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now?

news source

Zacks Investment Research • Nov 10, 2026

news preview

Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

news source

Zacks Investment Research • Nov 6, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Viatris Inc.

Open an M1 investment account to buy and sell Viatris Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in VTRS on M1